Furthermore, the inhibitory potentials of the synthesised compounds against certain phospholipases and proteases implicated in cancer and inflammatory disorders, in addition to α-amylase, α-glucosidase, and xanthine oxidase, managing metabolic syndrome are investigated with the aim of eradicating the risk factors for CRC or combatting the disease. Here, XDH is linked to metabolic syndrome.